1. Fertility preservation outcomes in women with gliomas: a retrospective case–control study
- Author
-
Taylor Nordan, Patrick Y. Wen, Elizabeth S. Ginsburg, Andrey V. Dolinko, Pietro Bortoletto, and Ann M. Thomas
- Subjects
Infertility ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,In vitro fertilisation ,business.industry ,medicine.medical_treatment ,Case-control study ,Cancer ,medicine.disease ,Embryo transfer ,03 medical and health sciences ,0302 clinical medicine ,Neurology ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Glioma ,medicine ,Neurology (clinical) ,Fertility preservation ,business ,030217 neurology & neurosurgery - Abstract
With advances in cancer therapy, reproductive-aged women can look forward to a life post-malignancy. Fortunately, fertility preservation (FP) may provide relief from potential infertility caused by cancer or associated caustic treatments. Outcomes of FP in pre-treatment reproductive-aged women with gliomas have not been previously characterized. Between 2007 and 2018, 10 patients undergoing FP prior to chemotherapy and/or radiation treatment for gliomas were identified at Brigham and Women’s Hospital. They were matched 3:1 to male-factor infertility patients by age ± 1 year. Patients with gliomas had significantly lower baseline anti-Mullerian hormone levels than male-factor infertility controls (2.37 vs 5.16 ng/mL, p = 0.002, log transformed). Despite higher starting (350 vs. 240 IU, p = 0.004) and total gonadotropin doses (4270 vs. 2270 IU, p
- Published
- 2020
- Full Text
- View/download PDF